GLP-1 & GIP Updates and Announcements
Let's walk through the Changes you will find in this updated PocketCard
Snapshot Overview of Changes
- The GLP-1 & GIP Meds PocketCard now includes two distinct versions—one for diabetes and one for weight management with max doses and indications. This side-by-side approach makes it easier to individualize treatment decisions based on a person’s health profile, age, and comorbidities.
- Wegovy 7.2mg High Dose (HD) version was added.
- Oral Wegovy, with 25mg max dose added.
- Rybelsus name updated to Oral Ozempic for 1.5 mg, 4 mg, and 9 mg doses.
- Mounjaro now indicated for peds 10-17 yrs.
Pharmacology Breakdown and More Details
Glucagon-like peptide-1 (GLP-1) receptor agonists and GLP/GIP class of medications have seen significant advancements in the past year and 2026 promises to offer even more advancements.
Semaglutide (Wegovy) for Weight Loss Updates – High Dose & Pediatric Approval
The FDA granted accelerated approval in March 2026 for a high-dose (HD) injectable version of Wegovy of 7.2 mg once weekly. Until now, the highest approved dose for Wegovy—the weight loss formulation of the GLP-1 receptor agonist semaglutide—was 2.4 mg weekly.
Many individuals on the maximum 2.4 mg dose eventually reach a weight loss plateau, prompting researchers to explore whether higher dosing could extend weight reduction. Clinical trials demonstrate that increasing the dose to 7.2 mg weekly can lead to additional weight loss of up to ~20–21% from baseline, representing a meaningful advancement for those needing further support.
As expected, gastrointestinal side effects increase with higher doses, particularly, nausea, vomiting, diarrhea and early satiety. As with the other incretin medications, encourage smaller, lower fat meals that are high in nutrients. Remind individuals to keep hydrated and if the nausea persists, they may benefit from anti-nausea medications.
Mounjaro Pediatric Approval Update: Expanding Treatment Options for Youth
A major step forward in pediatric diabetes care is the recent expansion of tirzepatide (Mounjaro) into younger populations. With emerging data and regulatory progress, tirzepatide is being recognized as a potential option for youth with type 2 diabetes and extra weight, offering another powerful new tool to improve metabolic measures for young people with diabetes.
This update reflects a broader shift toward earlier, more effective interventions in youth with diabetes and elevated body weight, aligning with current guidelines that emphasize person-centered, individualized care.
Oral Wegovy Update: Expanding Options with Higher-Dose Therapy
A new advancement in weight management is the availability of Oral Wegovy (oral semaglutide), now with dosing options up to a maximum of 25 mg once daily. This expanded dosing offers a non-injectable alternative for individuals seeking the benefits of GLP-1–based therapy for weight management, while maintaining meaningful efficacy.
As with other oral semaglutide formulations, administration technique is critical—it should be taken on an empty stomach with a small amount of water, with no food, beverages, or other medications for at least 30 minutes to optimize absorption.
Higher-dose oral therapy may help individuals who have reached a weight plateau or who require more intensive pharmacologic support, aligning with evolving treatment strategies that prioritize person-centered care and individualized therapy.
As always, it is important to provide guidance on gradual dose escalation and management of gastrointestinal side effects, ensuring individuals are supported every step of the way.
Rybelsus Rebranded: Introducing Oral Ozempic
In an effort to streamline GLP-1 therapy across formulations, Rybelsus (oral semaglutide) 1.5 mg, 4 mg, and 9 mg doses, is being rebranded as Oral Ozempic. The original Rybelsus 3, 7, and 14 doses will eventually be phased out. This naming alignment reflects the same active molecule—semaglutide—used in injectable Ozempic and Wegovy, helping reduce confusion and reinforce class familiarity among individuals and providers.
As with prior oral semaglutide formulations, proper administration remains key: it should be taken on an empty stomach with a small amount of water, with no food, beverages, or other medications for at least 30 minutes to ensure optimal absorption.
This update represents another step toward clarifying and simplifying diabetes treatment options.
New Once Weekly Insulin - Who Might Benefit Most?
We have also updated our Insulin PocketCard to include the newly approved ultra-long-acting insulin icodec.
This once weekly insulin may be especially valuable for:
- People with type 2 diabetes who struggle with taking daily injections.
- Individuals experiencing treatment fatigue
- Those who would benefit from simplified regimens
- Re-engaging patients hesitant to start insulin
This is where your role as a healthcare professional becomes even more powerful—matching the right therapy to the right person.
Our Insulin PocketCard Now includes icodec insulin.
We have also updated our Insulin PocketCard to include the newly approved ultra-long-acting insulin icodec.
This once weekly insulin may be especially valuable for:
- People with type 2 diabetes who struggle with taking daily injections.
- Individuals experiencing treatment fatigue
- Those who would benefit from simplified regimens
- Re-engaging patients hesitant to start insulin
This is where your role as a healthcare professional becomes even more powerful—matching the right therapy to the right person.
Final Thoughts
As healthcare professionals, staying current with these advancements allows us to:
- Provide evidence-based recommendations
- Support informed decision-making
- And most importantly, meet people where they are
Want to Stay Current on Innovations Like This?
Join us as we break down the latest in diabetes care, guidelines, and emerging therapies— you can bring confidence, clarity, and compassion to your clinical practice by joining our DiabetesEd Training Conference.
Join us live in San Diego for our
DiabetesEd Training Program
Brand new agenda for 2026!
🌟Updated Schedule: ADA Boot Camp, Tech, MNT & More
Live in Beautiful San Diego – Oct 22-23, 2026
Re-Ignite your Passion & Prepare for Diabetes Certification Exams
🎓 Earn 30+ CEs: AMA PRA Category 1 Credits™, ACPE, ANCC, and CDR!
📅
2-Day Conference
Oct 22–23, 2026
⏱️
15.5 Live CEs
+ 17 bonus CEs
🏅
CDCES & BC-ADM
Exam Prep + Renewal
📍
San Diego, CA
1.7 mi from airport
Advance Your Expertise and Prepare for Your Future
The field of diabetes care is expanding and evolving rapidly. This unique training conference will keep you on the cutting edge plus prepare you for certification exams. It also fulfills the Standards of Care renewal requirement. Join us for two days of intensive education that is fun and inspiring. Add on the optional Day 3 (Engaging the Disengaged), to complete your conference exeperience.
Day 1 – ADA/AACE Standards of Care Boot Camp
Coach Beverly and Diana Isaacs, PharmD, BC-ADM, CDCES co-lead an exciting day that brings the ADA and AACE Standards to life. Gain fresh insights, practical tools, and a deeper understanding of the latest in person-centered diabetes care. After attending, you will be empowered to share the latest in diabetes care with your colleagues and the people in your care.
Day 2 – Insulin, Tech, MNT and Case Studies
Take your knowledge to the next level with this intensive deep-dive into insulin therapy, dosing and pattern management with Dr. Diana Isaacs. Next, stay for the diabetes tech show-and-tell as Diana demonstrates the specs of the latest pumps and sensors. After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice. You will have a chance to put it all together as Coach Beverly leads you through a series of case studies that integrates content from Day 1 and Day 2.
Add-On Day 3 – Engaging the Disengaged
On Saturday, join this exceptional day-long program led by William H. Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management — tools to break through resistance and inspire change.
Read more below
🌟Registration Options at a Glance
📜 Essentials
Registration
+ Printed Syllabus
$559.00
🌟 Deluxe
Essentials
+ ADA Standards Book
$589.00
🏆 Complete – Best Value!
Deluxe
+ ADCES Review Guide e-Book
$669.00
5 Reasons to Attend
- Led by national experts 👩⚕️Dr. Diana Isaacs (Cleveland Clinic), Coach Beverly 🧢 (30+ years of experience), and Christine Craig (nutrition whiz).
- 🌴 Location makes for a great vacation
- Networking, walking paths, connection
- Ready yourself for the diabetes future🚀
- Have fun, win prizes, play DiaBingo 😄
What's Included?
- 🍽️ Healthy breakfasts, lunch, refreshments and coffee ☕
- 📘 100-page printed syllabus
- 🎤 2 days of engaging, expert-led education with case studies.
- 🎓 12 FREE online courses ($375 value)
- Free MedPocketCard & Coach Bev’s Book 📗 Healing through Connection.
Add on a 3rd Day!
Enroll in
ENGAGING THE DISENGAGED
Strategies for Promoting Behavior Change in Diabetes
October 24, 2026
Transform how you engage patients with diabetes — master behavior change, reduce distress, and overcome medication hesitancy.
Why do so many patients know what they should do — but still struggle to do it?
The answer lies in the psychology of diabetes.
In this transformative full-day course, world-renowned experts William H. Polonsky, PhD, CDCES, and Susan Guzman, PhD, from the Behavioral Diabetes Institute reveal the hidden psychosocial forces that drive — or derail — diabetes self-management.
You’ll walk away with a completely new toolkit for breaking through patient resistance, dissolving medication hesitancy, and creating clinical encounters that actually inspire change!
